Suppuration: Clinical Trials

683 trials for Suppuration, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

367 completed, 89 recruiting, 80 unknown, 50 terminated. 190 Not applicable, 134 Phase 2, 102 Phase 3, 63 Phase 4, 38 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable190Completed 101, Unknown 32, Terminated 19, Not yet recruiting 15, Recruiting 13, Withdrawn 8, Active not recruiting 1, Suspended 1
Phase 2134Completed 82, Recruiting 15, Terminated 13, Active not recruiting 9, Unknown 8, Withdrawn 4, Not yet recruiting 3
Phase 3102Completed 64, Terminated 10, Active not recruiting 9, Unknown 8, Recruiting 5, Not yet recruiting 3, Withdrawn 2, Enrolling by invitation 1
Phase 463Completed 33, Recruiting 10, Unknown 7, Terminated 5, Withdrawn 5, Not yet recruiting 3
Phase 138Completed 23, Recruiting 9, Active not recruiting 2, Not yet recruiting 2, Unknown 1, Withdrawn 1
Early Phase 111Completed 4, Recruiting 3, Withdrawn 2, Not yet recruiting 1, Unknown 1

Follow Suppuration: new trials by email Literature Review of Suppuration trials Research Report on Suppuration

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses
Methylene Blue, Lipid Emulsion, Insertion of optical fiber - Abscess
Phase 2Not yet recruitingUniversity of Rochester1502027-07-152026-11-17
A Study of SL-325 in Participants With Hidradenitis Suppurativa
SL-325, Placebo - Hidradenitis Suppurativa (HS)
Phase 2Not yet recruitingShattuck Labs, Inc.1502027-01-012026-11-13
Dose Reduced Alteplase in Managing Intrapleural Sepsis
Reduced Dose Alteplase, Standard Dose Alteplase - Complicated Parapneumonic Effusion, Empyema, Pleural
Phase 3Not yet recruitingVanderbilt University Medical Center2482027-01-012026-11-17
A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab
Hidradenitis Suppurativa
Not yet recruitingNovartis Pharmaceuticals342026-12-312026-11-10
Evaluating Antibiotic Course Upon Adequate Treatment of Empyema
shortened antibiotic course, Standard medical treatment - Pleural Empyema
Not applicableNot yet recruitingUniversity of Arizona502026-11-162026-10-07
A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
Hidradenitis Suppurativa
Not yet recruitingNovartis Pharmaceuticals1862026-11-132026-10-20
VATS or Intrapleural Enzymatic Therapy for Patients With Empyema.
VATS group, IET - Empyema, Pleural, Pleural Infections
Phase 4RecruitingAmsterdam UMC1642026-11-072026-11-10
Comparative Study Between Laparoscopic and Open Appendectomy of Complicated Appendicitis
Laparoscopic Appendectomy, Open Appendectomy - Appendicitis, Perforated Appendicitis
Not applicableNot yet recruitingAssiut University1002026-11-012026-10-16
Naproxen Versus Placebo as Adjunct Treatment of Cellulitis
enteric-coated naproxen, Cephalexin Tablets, Placebo - Cellulitis, Skin Disease, Infectious
Phase 3Not yet recruitingOttawa Hospital Research Institute8842026-11-012026-10-20
A Single Dose of Intravenous Penicillin as an Adjunct to Oral Penicillin in the Treatment of Acute Tonsillitis, Peritonsillar Phlegmon, and Peritonsillar Abscess
Benzylpenicillin, Isotonic NaCl (Placebo) - Acute Tonsillitis, Peritonsillar Abscess
Phase 4RecruitingTejs Ehlers Klug1542026-11-012026-11-04
Early Pathophysiology of Hidradenitis Suppurativa and Prediction of the Risk of Progression: a Prospective Cohort
Biological samples and questionnaires, Analysis of residual skin tissue - Hidradenitis Suppurativa (HS)
Not applicableNot yet recruitingAssistance Publique - Hôpitaux de Paris2002026-11-012026-11-06
A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
LOU064, Placebo - Hidradenitis Suppurativa
Phase 1RecruitingNovartis Pharmaceuticals302026-10-292026-11-10
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
Olatorepatide, Placebo - Hidradenitis Suppurativa
Phase 2RecruitingRegeneron Pharmaceuticals3002026-10-292026-11-10
Moxifloxacin Versus Clindamycin in the Management of Odontogenic Maxillofacial Infectious Processes
Clindamycin, Moxifloxacin (400 mg) - Odontogenic Infection, Maxillofacial Infection
Not applicableNot yet recruitingNishtar Medical University602026-10-012026-10-16
Does Adding a Fascial Layer to the Cartilage in Tympanoplasty for Large Tympanic Membrane Perforation Affect the Overall Results?
Conchal Cartilage and Perichondrium Tympanoplasty, Conchal Cartilage, Perichondrium, and Temporalis Fascia Tympanoplasty - Tympanic Membrane Perforation, Otitis Media
Not applicableNot yet recruitingAssiut University502026-10-012026-09-22
Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases
Psoriasis, Eczema/Atopic Dermatitis
Not yet recruitingMedisch Spectrum Twente10002026-10-012026-09-04
Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa
Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo - Hidradenitis Suppurativa (HS)
Phase 2Not yet recruitingUniversity of Massachusetts, Worcester402026-10-012026-09-10
Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis
Retention of Vernix Caseosa After Birth, Removal of Vernix Caseosa After Birth - Atopic Dermatitis
Not applicableRecruitingPontificia Universidad Catolica de Chile13832026-09-292026-09-30
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Soquelitinib - Hidradenitis Suppurativa (HS)
Phase 1RecruitingCorvus Pharmaceuticals, Inc.252026-09-172026-10-15
Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS)
Phase 2RecruitingHarrison Dermatology102026-09-102026-10-13

Showing 20 of 683. Sign in to see all of them.

Narrower conditions

Hidradenitis Suppurativa (283)  ·  Cellulitis (157)  ·  Abscess (111)  ·  Empyema (35)  ·  Empyema, Pleural (34)  ·  Abdominal Abscess (31)  ·  Infections (28)  ·  Skin Diseases (28)  ·  Hidradenitis (27)  ·  Dermatitis, Atopic (24)  ·  Psoriasis (23)  ·  Soft Tissue Infections (22)  ·  Wound Infection (22)  ·  Pneumonia (19)  ·  Skin Diseases, Bacterial (18)

Broader conditions

Infections (655)  ·  Skin and Connective Tissue Diseases (455)  ·  Skin Diseases, Infectious (440)  ·  Bacterial Infections and Mycoses (353)  ·  Pathological Conditions, Signs and Symptoms (343)  ·  Pathologic Processes (335)  ·  Bacterial Infections (334)  ·  Skin Diseases (320)  ·  Skin Diseases, Bacterial (302)  ·  Inflammation (300)  ·  Sweat Gland Diseases (276)  ·  Hidradenitis (256)  ·  Connective Tissue Diseases (173)  ·  Abscess (108)

Interventions

Vancomycin (19)  ·  Adalimumab (17)  ·  Clindamycin (17)  ·  Linezolid (14)  ·  secukinumab (14)  ·  Drainage (13)  ·  Trimethoprim, Sulfamethoxazole Drug Combination (13)  ·  Cephalexin (10)  ·  Daptomycin (10)  ·  Moxifloxacin (10)  ·  Saline Solution (10)  ·  Sodium Chloride (9)  ·  Tissue Plasminogen Activator (9)  ·  Amoxicillin-Potassium Clavulanate Combination (7)  ·  Aztreonam (7)

Sponsors

Novartis Pharmaceuticals (22)  ·  AbbVie (15)  ·  Incyte Corporation (12)  ·  GlaxoSmithKline (11)  ·  Assiut University (9)  ·  Pfizer (9)  ·  Henry Ford Health System (8)  ·  Children's Mercy Hospital Kansas City (6)  ·  Montefiore Medical Center (6)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (6)  ·  UCB Biopharma SRL (6)  ·  University of California, San Francisco (6)  ·  University of Miami (6)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (6)  ·  Assistance Publique - Hôpitaux de Paris (5)

Countries

United States (312)  ·  Canada (95)  ·  Germany (79)  ·  France (73)  ·  Spain (67)  ·  Poland (53)  ·  Italy (47)  ·  Netherlands (46)  ·  Australia (40)  ·  China (39)  ·  Greece (39)  ·  United Kingdom (39)  ·  Denmark (36)  ·  Belgium (30)  ·  Bulgaria (30)

Top investigators

Hadar Lev-Tov, MD (5)  ·  G. Ralph Corey, MD (4)  ·  Shawn D St. Peter, MD (4)

Results publications

PMID 27518661, PMID 29380251, PMID 30597021, PMID 30716446, PMID 31604104, PMID 34741280, PMID 34905144, PMID 34922058, PMID 36746171, PMID 41248770, PMID 42482599, PMID 42525209, PMID 20346539, PMID 20695801, PMID 21115456, PMID 22236226, PMID 23247938, PMID 24897082, PMID 27370913, PMID 27585969, PMID 29358292, PMID 32460374, PMID 32965495, PMID 33599960, PMID 34252397, PMID 34976290, PMID 34978076, PMID 38795716, PMID 39101698, PMID 39141589, PMID 39425517, PMID 40153232, PMID 40172122, PMID 40372667, PMID 40652434, PMID 40839197, PMID 41107641, PMID 41689425, PMID 42247110, PMID 42493571, PMID 10028110, PMID 10371477, PMID 11425832, PMID 11555797, PMID 11576584, PMID 12048413, PMID 12140476, PMID 12145720, PMID 12487041, PMID 12625969

NIH funding

2025 (9), 2023 (7), 2018 (5), 2009 (3), 2019 (3), 2004 (1), 2008 (1), 2015 (1), 2017 (1), I50HX002263 (1), K08AR080844 (1), K12TR004908 (1), K23DA054363 (1), KL2RR031974 (1), R01NR013888 (1)